Citius Oncology, Inc. CTOR
Citius Oncology, Inc. (Nasdaq: CTOR) is an oncology drug developer. Its lead program, LYMPHIR (denileukin diftitox-cdxl), is marketed for persistent or recurrent cutaneous T-cell lymphoma.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LYMPHIR | CTCL | protein/peptide | Approved |
Recent results and decisions
- Mar 10, 2026positive Completed Phase 1 of LYMPHIR plus pembrolizumab showed 24% ORR and 48% clinical benefit rate in 21 evaluable patients, with no unexpected safety signals in 25 evaluable.
The trial explored efficacy and demonstrated a 24 % objective response rate (ORR) and a 48 % clinical benefit rate (CBR, defined as complete response, partial response and/or stable disease for six months or greater) among 21 evaluable patients.
Filing - Mar 4, 2026positive Investigator-initiated Phase 1 (n=14) of LYMPHIR before CAR-T showed 86% ORR (57% CR, 29% PR), 1-year PFS 77%, no dose-limiting toxicities.
Overall response rate (ORR) was 86% at one month, including 57% complete responses (CR) and 29% partial responses (PR);
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.